On Monday, Anthem Inc (NYSE:ANTM)’s shares inclined 2.32% to $164.44.
Anthem Inc (ANTM) has placed a takeover bid for Cigna Corp. (CI). There have actually been 2 takeover bids in the last 10 days, the last one priced at $175 per share. The companies have been in talk aboution about the possibility of a takeover for a few months, but Cigna has thus far denied Anthem’s offers.
Cigna’s stocks surged to a 52-week high of $164 on heels of the news coming about, before decreasing to $153.43 to close out the day, a figure that is still a double digit enhance for the session. Anthem’s stock price saw an enhance of $3.75 or 2.33% to $164.46 as of the same time.
The health-insurance industry is in the midst of a major consolidation trend, and the news of Anthem’s bids comes at a time when the industry faces pressures to cut costs and explore all opportunities stemming from the Affordable Care Act. Because of the Act though, U.S. health insurers have been trading at all time highs due to the influx of new business. It also brought new fees that have affected providers’ profit margins.
Anthem, Inc., through its auxiliaries, operates as a health benefits company in the United States. It operates through three segments: Commercial and Specialty Business, Government Business, and Other. The company offers a spectrum of network-based managed care health benefit plans to large and small employer, individual, Medicaid, and senior markets. Its managed care plans comprise preferred provider organizations; health maintenance organizations; point-of-service plans; traditional indemnity plans and other hybrid plans, such as consumer-driven health plans; and hospital only and limited benefit products.
Sanofi SA (ADR) (NYSE:SNY)’s shares dropped -2.29% to $49.44.
Sanofi SA (ADR) (SNY) and Regeneron Pharmaceuticals, Inc. declared that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S. Food and Drug Administration (FDA) recommended the approval of the investigational therapy Praluent® (alirocumab) Injection. The Committee voted 13 to 3 (with no abstentions) that Sanofi and Regeneron had sufficiently established that the low-density lipoprotein cholesterol (LDL-C, or bad cholesterol) lowering benefit of Praluent exceeds its risks to support approval in one or more patient populations.
The Committee’s recommendation was based on Praluent’s benefit-risk profile, following review of efficacy and safety data from more than 5,000 patients across 10 pivotal Phase 3 double-blind trials ranging from six months to two years. Clinical data from the ODYSSEY Phase 3 program show comprising, positive results in reducing LDL-C. Common adverse events that were more frequently stated in patients treated with Praluent than the control groups comprised of injection site reaction and pruritus (itching).
Sanofi researches, develops, and markets various therapeutic solutions. Its products comprise diabetes solutions, counting Lantus, Apidra, and Insuman that are human insulin analogs; Amaryl, an oral sulfonylurea; Lyxumia, a glucagon-like peptide-1 receptor agonist; and Afrezza, an inhaled insulin to improve glycemic control, in addition to Toujeo, an insulin glargine.
At the end of Monday’s trade, SYSCO Corporation (NYSE:SYY)‘s shares surged 0.24% to $37.01.
SYSCO Corporation (SYY) declared that its Board of Directors declared a regular quarterly cash dividend of $0.30 per share, payable on July 24, 2015, to common shareholders of record at the close of business on July 2, 2015.
Sysco Corporation, through its auxiliaries, markets and distributes a range of food and related products primarily to the foodservice or food-away-from-home industry. It operates in Broadline and SYGMA segments. The company distributes a line of frozen foods, such as meats, seafood, fully prepared entrees, fruits, vegetables, and desserts; a line of canned and dry foods; fresh meats; dairy products; beverage products; imported specialties; and fresh produce.
Banco Bilbao Vizcaya Argentaria SA (ADR) (NYSE:BBVA), ended its Monday’s trading session with -1.86% loss, and closed at $10.02.
Banco Bilbao Vizcaya Argentaria SA (ADR) (BBVA) launched its digital wallet, giving clients a convenient new way to monitor and safeguard their BBVA Compass credit and debit cards.
BBVA Wallet, available as an app for iPhone and Android devices, gives clients a real-time view of card transactions and the ability to temporarily or permanently deactivate lost or stolen credit cards. The service also allows the bank’s credit card holders to set up transaction alerts and change their PINs.
BBVA Wallet is an extension of the bank’s efforts to give clients greater control of their finances and to make banking faster and easier, said BBVA Compass Chief Digital Banking Officer Jeff Dennes.
BBVA Compass’ parent company, BBVA, first launched BBVA Wallet in 2013 in Spain and has since built a following of more than 570,000 users. The service was introduced to clients in Chile and Mexico earlier this spring.
Dennes said BBVA Wallet was built in-house, allowing the bank to introduce enhancements to the service at its own pace.
Banco Bilbao Vizcaya Argentaria, S.A. engages in the retail banking, wholesale banking, asset administration, and private banking businesses primarily in Spain, Eurasia, Mexico, South America, and the United States. It offers deposit products, counting personal accounts, housing accounts, savings accounts, deposit accounts, etc.; and loan products, such as personal loans, mortgages, etc.; credit cards; investment products comprising mutual funds, warrants, and pension plans; and telephone and on-line banking services, in addition to ATMs for individual customers.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
